disease 1,837 words KG: ent-dise-b93267d6 2026-03-22
kind:diseasesection:diseasesstate:published
Contents

Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

Disease Info
AgeThe strongest risk factor; LATE is overwhelmingly a disease of advanced age
Female sexWomen appear to be at modestly higher risk
Genetic factorsVariants in TMEM106B, GRN (encoding progranulin, ABCC9, KCNMB2, and APOE, a nuclear RNA-binding protein that normally regulates mRNA splicing, stability, and transport. In LATE:
Cerebrovascular diseaseArteriolosclerosis, microinfarcts, and white matter changes
Lewy body pathology[alpha-synuclein/proteins/alpha deposits may also co-occur
DatabasesOMIMOrphanetClinicalTrialsPubMed

Knowledge Graph

Related Hypotheses (18)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.42
p38α Inhibitor and PRMT1 Activator Combination to Restore Ph
Score: 0.61
HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43
Score: 0.60
RNA Granule Nucleation Site Modulation
Score: 0.48

Related Analyses (9)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived

Related Experiments (8)

Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40